Skip to main content

Clinical Trials Using Rituximab

Review the clinical trials studying rituximab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 122

CtDNA-Guided Mosunetuzumab Consolidation Therapy for the Treatment of Diffuse Large B-cell Lymphoma in Older Adults
Status: Active
Location: 2 locations
Roginolisib in Combination with Venetoclax and Rituximab for the Treatment of Refractory or Relapsed Chronic Lymphocytic Leukemia
Status: Active
Location: 2 locations
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Status: Active
Location: 3 locations
Pembrolizumab in Combination with Chemotherapy for the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma
Status: Active
Location: 2 locations
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Status: Active
Location: Long Island Jewish Medical Center, New Hyde Park, New York
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Bridging Therapy with Loncastuximab Tesirine and Rituximab for the Treatment of Relapsed/Refractory Large B-cell Lymphoma in Patients Undergoing CD19 CAR T-cell Therapy
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cladribine and Rituximab in Treating Patients with Hairy Cell Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax and Rituximab for the Initial Treatment of Older Patients with Untreated Mantle Cell Lymphoma
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Rituximab and Zanubrutinib for the Treatment of Patients with Marginal Zone Lymphoma or Follicular Lymphoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Tafasitamab in Combination with Lenalidomide and Rituximab for the Treatment of Follicular Lymphoma and Marginal Zone Lymphoma
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Consolidation Therapy (R-EPOCH) for the Treatment of Patients with Posttransplant Lymphoproliferative Disorder
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Combination Chemotherapy in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Hematopoietic Cell Transplant with Individualized Reduced Intensity Conditioning and Post-Transplant Cyclophosphamide for the Treatment of Patients with Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Haploidentical Stem Cell Transplant with Umbilical Cord Blood Transplant for the Treatment of Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
PACIFIC: Primary Mediastinal large B-cell lymphoma treated with Antibody therapy, Checkpoint Inhibitor in Frontline with ImmunoChemotherapy
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax, Tagraxofusp, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Zanubrutinib with R-CHOP for the Treatment of Patients with Diffuse Large B-Cell Lymphoma
Status: Active
Location: VCU Massey Comprehensive Cancer Center, Richmond, Virginia
Mini Hyper-CVD with Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for the Treatment of Relapsed B-Cell Acute Lymphocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
T Cell Receptor Alpha/Beta Depletion Peripheral Blood Stem Cell Transplantation for the Prevention of Graft Versus Host Disease in Children and Adults with Hematological Malignancies
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota